A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
NCT05262959
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Donafenib
Interventions
DRUG:
Donafenib, PD-1
PROCEDURE:
TACE
Sponsor
Shanghai Zhongshan Hospital